PAFAH1B2

Across TCGA pan-cancer cohorts, PAFAH1B2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAFAH1B2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher PAFAH1B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAFAH1B2 expression acts as an unfavorable survival marker.

PRAD, LUSC, and UCEC are the cancer types where PAFAH1B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.273	0.732	.033	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAFAH1B2–PRAD (DFS)

Open the PRAD breakdown →